Surmontil

Nocturnal Enuresis, Insomnia, Depression

Treatment

1 FDA approval

20 Active Studies for Surmontil

What is Surmontil

Trimipramine

The Generic name of this drug

Treatment Summary

Amitriptyline is a type of antidepressant drug similar to imipramine with added benefits of reducing allergy symptoms and promoting sleep.

Surmontil

is the brand name

image of different drug pills on a surface

Surmontil Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Surmontil

Trimipramine

1990

24

Approved as Treatment by the FDA

Trimipramine, also known as Surmontil, is approved by the FDA for 1 uses such as Depression .

Depression

Effectiveness

How Surmontil Affects Patients

Trimipramine is a type of antidepressant that works by influencing the levels of two important brain chemicals, norepinephrine and serotonin. It takes a few weeks to experience the full effects of this drug. It is also used to treat pain, particularly nerve-related pain. It is thought to work by altering certain receptors in the brain and influencing the opioid system, which helps to reduce pain. Finally, it is sometimes used to prevent migraines, though it is not effective in treating a migraine once it has started.

How Surmontil works in the body

Trimipramine works differently than other antidepressants. It works by blocking the reabsorption of two important chemicals in the brain: norepinephrine and serotonin. This allows these chemicals to stay in the brain longer, which leads to an antidepressant effect.

When to interrupt dosage

The indicative dose of Surmontil is contingent upon the acknowledged affliction, including Insomnia, Nocturnal Enuresis and Depression. The quantity of dosage vacillates, as per the delivery technique (e.g. Capsule or Tablet - Oral) featured in the table beneath.

Condition

Dosage

Administration

Nocturnal Enuresis

25.0 mg, , 100.0 mg, 50.0 mg, 75.0 mg, 12.5 mg

, Capsule, Oral, Capsule - Oral, Tablet - Oral, Tablet

Insomnia

25.0 mg, , 100.0 mg, 50.0 mg, 75.0 mg, 12.5 mg

, Capsule, Oral, Capsule - Oral, Tablet - Oral, Tablet

Depression

25.0 mg, , 100.0 mg, 50.0 mg, 75.0 mg, 12.5 mg

, Capsule, Oral, Capsule - Oral, Tablet - Oral, Tablet

Warnings

Surmontil Contraindications

Condition

Risk Level

Notes

Heart Attack

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Surmontil.

Common Surmontil Drug Interactions

Drug Name

Risk Level

Description

Acepromazine

Major

Trimipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.

Alfuzosin

Major

Trimipramine may increase the hypotensive activities of Alfuzosin.

Aripiprazole

Major

Trimipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.

Aripiprazole lauroxil

Major

Trimipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole lauroxil.

Asenapine

Major

Trimipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Asenapine.

Surmontil Toxicity & Overdose Risk

Overdosing on phenobarbital can lead to agitation, confusion, seizures, enlarged pupils, difficulty concentrating, drowsiness, seeing or hearing things that are not there, very high fever, abnormal heart rate, low body temperature, stiff muscles, exaggerated reflexes, dangerously low blood pressure, stupor, and vomiting.

image of a doctor in a lab doing drug, clinical research

Surmontil Novel Uses: Which Conditions Have a Clinical Trial Featuring Surmontil?

687 active trials are assessing the capability of Surmontil to alleviate Insomnia, Depression and Nocturnal Enuresis.

Condition

Clinical Trials

Trial Phases

Nocturnal Enuresis

1 Actively Recruiting

Not Applicable

Insomnia

0 Actively Recruiting

Depression

305 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Surmontil Reviews: What are patients saying about Surmontil?

1.7

Patient Review

12/26/2007

Surmontil for Depression

I was diagnosed with acute depression following a heart attack and triple bypass surgery in 1989. My treating psychiatrist prescribed me Surmontil, which I took as directed. However, I found that I was very fatigued all day long and still needed to sleep for several hours during the day on top of a full night's sleep. Additionally, I experienced frequent irregular heartbeats and palpitations.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about surmontil

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does Surmontil help sleep?

"Trimipramine, branded as Surmontil, is a tricyclic antidepressant used in the treatment of depression. Its sedative properties have led to it being used to "brighten up" dreams by disrupting the rapid eye movement (REM) phase of sleep."

Answered by AI

What is Surmontil used for?

"This medication is designed to treat patients who are suffering from depression. The main goal of trimipramine, a tricyclic antidepressant, is to restore the balance of neurotransmitters in the brain. This will, in turn, improve the patient's mood and sense of well-being, allowing them to enjoy everyday life more."

Answered by AI

What type of antidepressant is Surmontil?

"Generic Surmontil is a tricyclic antidepressant used to treat symptoms of depression."

Answered by AI

What is the generic name for Surmontil?

"Trimipramine is a drug used to treat depression. It is also used to treat anxiety and insomnia. It has weak antipsychotic effects."

Answered by AI

Clinical Trials for Surmontil

Image of The Korean Association of West Florida in Tampa, United States.

Mobile App Mindfulness for Mental Health

18+
All Sexes
Tampa, FL

The goal of this clinical trial (single-arm pilot trial) is to learn whether a mobile application-based mindfulness intervention can improve mental health outcomes in older Korean immigrants aged 60 years and older. The main questions it aims to answer are whether the 8-week mobile app-based mindfulness intervention is feasible and acceptable, as indicated by recruitment, retention, and adherence rates, and whether participation in the intervention leads to improvements in positive psychological well-being (e.g., positive affect, optimism, life engagement, and mindfulness) and reductions in adverse mental health outcomes (e.g., anxiety, depressive symptoms, and perceived stress). Participants will complete baseline and post-intervention assessments, receive training on how to use the mobile mindfulness application, engage with the app for approximately 8 weeks (recommended 10-15 minutes per day), and participate in weekly check-ins to support engagement and address any challenges encountered during the intervention.

Waitlist Available
Has No Placebo

The Korean Association of West Florida (+1 Sites)

Soonhyung Kwon

Image of Brown University in Providence, United States.

Mindfulness-Based Intervention for Mental Health

18 - 24
All Sexes
Providence, RI

The goal of this clinical trial (single-arm feasibility study) is to examine the feasibility, acceptability, and preliminary efficacy of a mindfulness-based, app-delivered intervention to address mental health and emotion regulation challenges in young adults with early life adversities (ELAs). The main questions it aims to answer is: \- Will young adults find the Growth, Empowerment, and Mindfulness (GEM) intervention to be both feasible and acceptable, as demonstrated by participants' engagement and quantitative/qualitative feedback? Additionally, it aims to answer: * Will GEM intervention demonstrate preliminary efficacy in improving outcome measures including depression, anxiety? * Are improvements in mindfulness and sleep, as well as reductions in rumination, mechanisms of action underlying the improvements in psychological and behavioral outcomes of the intervention? Participants will be asked to: * participate in GEM, which integrates app-based intervention content, formal and informal mindfulness practices, weekly Zoom group sessions, and ecological momentary intervention (EMI) delivery * complete baseline, post-intervention, and 3-month follow-up assessments * complete weekly assessments and daily ecological momentary assessments (EMAs) during the intervention delivery * wear Fitbit for researchers to collect sleep-related data

Recruiting
Has No Placebo

Brown University

Shufang Sun, PhD

Image of Michael E. DeBakey VA Medical Center, Houston, TX in Houston, United States.

Behavioral Activation-Guided Self-Help for Depression

18+
All Sexes
Houston, TX

Symptoms of depression are highly prevalent among Veterans. However, fewer than 30% of individuals with these symptoms receive any psychotherapy in the Veterans Health Administration (VHA). This is due to many factors, which may include provider availability and patient preferences. Guided self-help (GSH), which involves coaching sessions with patients who are following a fully developed self-help program, has the potential to increase access to care for these Veterans, particularly if implemented within a stepped care model of mental health treatment delivery and if delivered by a diverse set of providers. The VHA's primary care-mental health integration (PCMHI) service, which focuses on short courses of care for mild to moderate symptoms, may be an ideal place in which to deploy GSH. The current project seeks conduct a pilot randomized trial of a GSH program for depression adapted for PCMHI based on behavioral activation.

Waitlist Available
Has No Placebo

Michael E. DeBakey VA Medical Center, Houston, TX

Maribel Plasencia, BA MS PhD

Have you considered Surmontil clinical trials?

We made a collection of clinical trials featuring Surmontil, we think they might fit your search criteria.
Go to Trials
Image of UC San Diego Health Psychiatry in San Diego, United States.

Medi-TBS for Depression

18 - 65
All Sexes
San Diego, CA

Repetitive Transcranial Magnetic stimulation (rTMS) is an FDA-approved therapy for treatment resistant depression (TRD) that involves brief magnetic stimulation pulses on the dorsolateral prefrontal cortex (DLPFC) brain region. But studies of rTMS alone show remission rates of \~30%. Additionally, rTMS has not been shown to improve cognitive functioning that may be an independent factor predicting treatment success. This study will develop a novel multimodal treatment, which combines intermittent theta burst stimulation (iTBS) - a type of rTMS with digital mindfulness training to engage brain plasticity, enhance cognition and alleviate depression symptoms in individuals with TRD.

Phase 2
Recruiting

UC San Diego Health Psychiatry

Image of UF World Equestrian Center in Ocala, United States.

ONE-D TMS + D-Cycloserine for Depression and Concussion

18 - 65
Female
Ocala, FL

Concussion and depression have long been recognized to be intertwined pathologies.1-3 Although female athletes are more likely to suffer from mental health symptoms than males athletes following a concussion,2 research in this area has been largely biased toward males.4 Recently functional MRI (fMRI) studies5 in concussed athletes have established that there are patterns of local alterations in neural connectivity in the frontal cortex that demonstrate anatomic congruency with transcranial magnetic stimulation (TMS) studies that mapped alternations in neural connectivity to functional and somatic symptoms.6 Thus, there is potential that TMS treatment could decrease both symptom profiles, revolutionizing comorbid treatment options. Possible Benefits: Previous studies have showed a 70% remission rate for depression symptoms. It is possible that participants could have improvement in depressive or concussive symptoms after the ONE-D TMS treatment.

Phase 2 & 3
Waitlist Available

UF World Equestrian Center

Sara Gould, MD

Image of CVT in Centennial, United States.

Treatment for Anxiety Disorders

18 - 70
All Sexes
Centennial, CO

The goal of this hybrid implementation-effectiveness study is to learn about the effectiveness and appropriateness of "Trauma-Informed and Culturally-Responsive Integrated Massage Therapy" (TCI-Massage) for torture and war trauma survivors. The study aims are: • Examine the uptake of TCI-Massage within CVT by assessing key implementation science outcomes of acceptability and appropriateness among refugees and asylum seekers from diverse cultural backgrounds. • Examine the integration of massage therapy into the current psychosocial care model used at CVT. • Examine the effectiveness of TCI-Massage for torture and war trauma survivors to reduce distress (mental health symptoms, chronic pain, and HRV) and improve coping (interoceptive awareness and social functioning). Treatment group participants will participate in psychosocial care services + TCI-Massage, which the control group will only participate in psychosocial care services

Waitlist Available
Has No Placebo

CVT

Have you considered Surmontil clinical trials?

We made a collection of clinical trials featuring Surmontil, we think they might fit your search criteria.
Go to Trials
Image of Northwestern University in Chicago, United States.

Mothers and Babies Program for Depression in Parents of Children With Down Syndrome

18+
All Sexes
Chicago, IL

Goal: This R34 study will pilot an adaptation for the Mothers and Babies (MB) program for expectant and new parents of infants with Down syndrome (MBDS). Background: Expectant and new parents of infants with Down syndrome are at high risk for perinatal depression. Perinatal depression is both independently, and exponentially associated with long-term adverse neurodevelopmental consequences for infants with Down syndrome. MB is a cognitive-behavioral intervention designed to prevent perinatal depression. MB as one of the two most effective counseling interventions for perinatal depression prevention, with moderate to large effects sizes found across a series of randomized controlled trials (RCTs). However, research suggests that expectant and new parents of children with Down syndrome may have needs that standard MB does not address. Significance: This project will pilot a Down syndrome adaptation to MB, MBDS designed to target mechanisms of grief/loss and social support; and assess whether changes in the target mechanisms are associated with changes in depressive symptoms and parental sensitivity and responsivity to the infant. Innovation: The proposed project is innovative in three ways. First, the investigators plan to conduct the first pilot of a perinatal depression prevention intervention specifically designed for expectant and new parents of infants with Down syndrome. Second, the investigators plan to include fathers, nonbinary, and transgender parents to target symptoms of depression, rather than as simply a support person for maternal depressive symptom reduction. Third, the investigators plan to use a group format to establish cohorts of families of infants with Down syndrome of similar developmental stages. Design: Human-centered design and an open trial will inform a subsequent small randomized controlled clinical pilot to test the feasibility of the study protocol in preparation for a larger randomized controlled trial (RCT). Population: New and expectant parents of infants with Down syndrome. Outcomes: All aspects of the study protocol (e.g., condition allocation, treatment and control condition procedures, data collection, etc.) will be operationalized in preparation for the subsequent RCT. The investigators will assess MBDS effectiveness on target mechanisms of grief/loss and social support; and assess whether changes in the target mechanisms are associated with changes in depressive symptoms and parental sensitivity and responsivity to the infant.

Waitlist Available
Has No Placebo

Northwestern University

Heather J Risser

Image of San Diego State University in San Diego, United States.

Sleep Health Program for Marines

18+
All Sexes
San Diego, CA

The goal of this study is to test a sleep health program designed specifically for U.S. Marine Corps personnel. Researchers want to determine if this program helps Marines improve the participants sleep quality and overall mental health. The study will evaluate whether the program improves sleep quality and duration and reduces symptoms of depression, anxiety, PTSD, and suicide ideation. There are three distinct sleep health programs that will be evaluated; participants will be randomly assigned to one of five groups to receive different combinations of the sleep health programs. To measure results, researchers will use participant surveys for all enrolled participants and wearable sleep-tracking devices for a sub-set of participants. The study team expects that Marines who receive the most comprehensive version of the program will show the greatest improvements in sleep and psychological well-being.

Phase 2
Recruiting

San Diego State University

Emily Schmied, PhD

Image of University of Michigan in Ann Arbor, United States.

Virtual Reality for Depression in Multiple Sclerosis

18+
All Sexes
Ann Arbor, MI

This trial explores the use of immersive virtual reality (VR) nature-based experiences as a supplementary treatment for depression in individuals with progressive multiple sclerosis (MS). This study will evaluate the feasibility and efficacy of at-home VR deployment using the Apple Vision Pro, an advanced device that offers enhanced resolution, immersion, and usability compared to earlier VR systems. The study hypotheses include: * The integration of VR nature-based experiences with standard care will be feasible, acceptable, and will result in greater reductions in depressive symptoms compared to standard care or VR-only interventions. * The integration of VR nature-based experiences with standard care will result in greater reductions in stress and anxiety, better sleep, less insomnia, and improved fatigue compared to standard care alone or VR-only interventions.

Recruiting
Has No Placebo

University of Michigan

Hala Darwish, PhD

Apple Inc.

Image of Medical University of South Carolina (MUSC), Brain Stimulation Laboratory Institute of Psychiatry in Charleston, United States.

Mindfulness Training for Depression

18 - 80
All Sexes
Charleston, SC

This NIH-funded single-arm pilot tests the feasibility, acceptability, and preliminary effects of embedding brief guided mindfulness practice (via the Waking Up smartphone app) into the inter-session intervals of clinically administered accelerated intermittent theta-burst stimulation (aiTBS) for major depressive disorder (MDD). Participants receive aiTBS as standard clinical care at MUSC; the research intervention is daily guided mindfulness practice during the aiTBS course. Outcomes include feasibility/acceptability, changes in state mindfulness and hedonic tone (Day 0 to Day 5), perceived ease of meditation, trait mindfulness at 4 and 12 weeks, and durability of antidepressant response (PHQ-9) at 4 and 12 weeks.

Waitlist Available
Has No Placebo

Medical University of South Carolina (MUSC), Brain Stimulation Laboratory Institute of Psychiatry

Clayton Olash, MD

Have you considered Surmontil clinical trials?

We made a collection of clinical trials featuring Surmontil, we think they might fit your search criteria.
Go to Trials